Skip to main content

Advertisement

SpringerLink
Log in

Cytomegalovirus and multiple sclerosis risk

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343(13):938–952

    Article  PubMed  CAS  Google Scholar 

  2. Ascherio A, Munger KL (2007) Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 61(4):288–299

    Article  PubMed  Google Scholar 

  3. Zivadinov R, Nasuelli D, Tommasi MA et al (2006) Positivity of cytomegalovirus antibodies predicts a better clinical and radiological outcome in multiple sclerosis patients. Neurol Res 28(3):262–269

    Article  PubMed  CAS  Google Scholar 

  4. Ascherio A, Munger KL, Lennette ET et al (2001) Epstein–Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286(24):3083–3088

    Article  PubMed  CAS  Google Scholar 

  5. Buljevac D, van Doornum GJ, Flach HZ et al (2005) Epstein–Barr virus and disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 76(10):1377–1381

    Article  PubMed  CAS  Google Scholar 

  6. Coyle PK, Sibony PA (1987) Viral specificity of multiple sclerosis tear immunoglobulins. J Neuroimmunol 14(2):197–203

    Article  PubMed  CAS  Google Scholar 

  7. Höllsberg P, Hansen HJ, Haahr S (2003) Altered CD8 + T cell responses to selected Epstein–Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol 132(1):137–143

    Article  PubMed  Google Scholar 

  8. Hopkins RS, Indian RW, Pinnow E, Conomy J (1991) Multiple sclerosis in Galion, Ohio: prevalence and results of a case-control study. Neuroepidemiology 10(4):192–199

    Article  PubMed  CAS  Google Scholar 

  9. Levin LI, Munger KL, O’Reilly EJ, Falk KI, Ascherio A (2010) Primary infection with the Epstein–Barr virus and risk of multiple sclerosis. Ann Neurol 67(6):824–830

    PubMed  Google Scholar 

  10. Martínez-Rodríguez JE, Saez-Borderías A, Munteis E, Romo N, Roquer J, López-Botet M (2010) Natural killer receptors distribution in multiple sclerosis: relation to clinical course and interferon-beta therapy. Clin Immunol 137(1):41–50

    Article  PubMed  Google Scholar 

  11. Myhr KM, Riise T, Barrett-Connor E et al (1998) Altered antibody pattern to Epstein–Barr virus but not to other herpes viruses in multiple sclerosis: a population based case-control study from western Norway. J Neurol Neurosurg Psychiatry 64(4):539–542

    Article  PubMed  CAS  Google Scholar 

  12. Pandit L, Malli C, D’Cunha A, Shetty R, Singhal B (2013) Association of Epstein–Barr virus infection with multiple sclerosis in India 325(1–2):86–89

    CAS  Google Scholar 

  13. Provinciali L, Laurenzi MA, Vesprini L et al (1988) Immunity assessment in the early stages of amyotrophic lateral sclerosis: a study of virus antibodies and lymphocyte subsets. Acta Neurol Scand 78(6):449–454

    Article  PubMed  CAS  Google Scholar 

  14. Sanadgol N, Ramroodi N, Ahmadi GA et al (2011) Prevalence of cytomegalovirus infection and its role in total immunoglobulin pattern in Iranian patients with different subtypes of multiple sclerosis. New Microbiol 34(3):263–274

    PubMed  Google Scholar 

  15. Vartdal F, Vandvik B, Norrby E (1980) Viral and bacterial antibody responses in multiple sclerosis. Ann Neurol 8(3):248–255

    Article  PubMed  CAS  Google Scholar 

  16. Wandinger K, Jabs W, Siekhaus A et al (2000) Association between clinical disease activity and Epstein–Barr virus reactivation in MS. Neurology 55(2):178–184

    Article  PubMed  CAS  Google Scholar 

  17. Jafari N, Melles DC, Broer L, van Duijn CM, van Doornum GJJ, Hintzen RQ (2011) Higher EBV anti-early antigen IgG titres in MS patients of a Dutch genetic isolate: genes or environment? Data presented at the 5th Joint triennial congress of the European and American Committees for treatment and research in multiple sclerosis, Amsterdam, The Netherlands, 19–22 Oct 2011

  18. DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A (2006) Epstein–Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 63(6):839–844

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Dr Naghmeh Jafari (Rotterdam, The Netherlands), Dr Kassandra Munger (Boston, USA) and Professor Lekha Pandit (Mangalore, India) for kindly providing us with raw data from their studies. SVR had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Conflicts of interest

This study received no funding. Ms. Julia Pakpoor reports no disclosures. Miss Jina Pakpoor reports no disclosures. Dr Giulio Disanto reports no disclosures. Prof. Giovannoni serves on scientific advisory boards for Merck Serono, Biogen Idec and Vertex Pharmaceuticals; served on the editorial board of Multiple Sclerosis; has received speaker honoraria from Bayer Schering Pharma, Merck Serono, Biogen Idec, Pfizer Inc., Teva Pharmaceutical Industries Ltd.—Sanofi-Aventis, Vertex Pharmaceuticals, Genzyme Corp., Ironwood and Novartis; has served as a consultant for Bayer Schering Pharma, Biogen Idec, GlaxoSmithKline, Merck Serono, Protein Discovery Laboratories, Teva Pharmaceutical Industries Ltd.—Sanofi-Aventis, UCB, Vertex Pharmaceuticals, GW Pharma, Novartis and FivePrime; serves on the speakers bureau for Merck Serono; and has received research support from Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, UCB, Merz Pharmaceuticals, LLC, Teva Pharmaceutical Industries Ltd.—Sanofi-Aventis, GW Pharma and Ironwood. Dr. Ramagopalan reports no disclosures. The author(s) declare(s) that there is no conflicts of interest.

Author information

Authors and Affiliations

  1. Medical Research Council Functional Genomics Unit and Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK

    Julia Pakpoor, Giulio Disanto & Sreeram V. Ramagopalan

  2. School of Clinical Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK

    Jina Pakpoor

  3. Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London, E1 2AT, UK

    Gavin Giovannoni & Sreeram V. Ramagopalan

Authors
  1. Julia Pakpoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jina Pakpoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giulio Disanto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gavin Giovannoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sreeram V. Ramagopalan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sreeram V. Ramagopalan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pakpoor, J., Pakpoor, J., Disanto, G. et al. Cytomegalovirus and multiple sclerosis risk. J Neurol 260, 1658–1660 (2013). https://doi.org/10.1007/s00415-013-6912-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-013-6912-4

Keywords

Search

Navigation